Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
89,600,000
-
Total 13F shares
-
63,876,196
-
Share change
-
+1,961,324
-
Total reported value
-
$847,014,395
-
Put/Call ratio
-
37%
-
Price per share
-
$13.26
-
Number of holders
-
129
-
Value change
-
+$20,551,038
-
Number of buys
-
82
-
Number of sells
-
36
Institutional Holders of Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) as of Q3 2023
As of 30 Sep 2023,
Verve Therapeutics, Inc. - Common Stock, par value $0.001 per share (VERV) was held by
129 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
63,876,196 shares.
The largest 10 holders included
Alphabet Inc., FMR LLC, ARK Investment Management LLC, VANGUARD GROUP INC, BlackRock Inc., STATE STREET CORP, Casdin Capital, LLC, FEDERATED HERMES, INC., JPMORGAN CHASE & CO, and Nikko Asset Management Americas, Inc..
This page lists
129
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.